Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. AbbVie Inc.
  6. News
  7. Summary
    ABBV   US00287Y1091

ABBVIE INC.

(ABBV)
  Report
Delayed Nyse  -  04:03:09 2023-02-06 pm EST
145.02 USD   -0.12%
02/06Health Care Down on Growth Doubts -- Health Care Roundup
DJ
02/06Wall St edges lower as Fed fears mount
RE
02/06Wall St edges lower on Fed fears; Tyson Foods slides
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Credit Suisse Starts AbbVie at Outperform With $170 Price Target

11/18/2022 | 08:09am EST
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ABBVIE INC.
02/06Health Care Down on Growth Doubts -- Health Care Roundup
DJ
02/06Wall St edges lower as Fed fears mount
RE
02/06Wall St edges lower on Fed fears; Tyson Foods slides
RE
02/06AbbVie Said to Push Two New Immune Medicines, Lift $2 Billion Cap on Dealmaking
MT
02/06BMO Capital Adjusts Price Target on AbbVie to $167 From $169, Maintains Outperform Rati..
MT
02/06U.S. employment weighs on markets
MS
02/06Abbvie plans to lift $2 billion cap on deals - WSJ
RE
02/06North American Morning Briefing: Payrolls Shocker, China..
DJ
02/03S&P 500 Posts Weekly Climb Led by Communication Services, Technology Sectors as FOMC Sl..
MT
02/02Global markets live: ABB, Infineon, Shell, Metlife, Boeing...
MS
More news
Analyst Recommendations on ABBVIE INC.
More recommendations
Financials (USD)
Sales 2022 58 284 M - -
Net income 2022 14 494 M - -
Net Debt 2022 54 506 M - -
P/E ratio 2022 17,5x
Yield 2022 3,91%
Capitalization 256 B 256 B -
EV / Sales 2022 5,33x
EV / Sales 2023 5,55x
Nbr of Employees 50 000
Free-Float 97,4%
Chart ABBVIE INC.
Duration : Period :
AbbVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 145,02 $
Average target price 162,24 $
Spread / Average Target 11,9%
EPS Revisions
Managers and Directors
Richard A. Gonzalez Chairman & Chief Executive Officer
Robert A. Michael Vice Chairman & President
Scott T. Reents Chief Financial Officer & Executive Vice President
Thomas J. Hudson VP, Head-Oncology Discovery & Early Development
Azita Saleki-Gerhardt Executive Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
ABBVIE INC.-10.27%256 378
JOHNSON & JOHNSON-7.52%430 370
ELI LILLY AND COMPANY-7.31%322 186
NOVO NORDISK A/S0.37%309 611
ROCHE HOLDING AG-2.81%269 030
MERCK & CO., INC.-6.24%260 994